Androgens : production, functions, and disorders / Berkley F. Thompson and Devon J. Robinson, editors.
Material type:
TextSeries: Endocrinology research and clinical developmentsPublisher: New York : Nova Biomedical/Nova Science Publishers, Inc., [2012]Description: 1 online resourceContent type: - text
- computer
- online resource
- 9781620811887
- 162081188X
- 612/.405 23
- QP572.A5
| Item type | Home library | Collection | Call number | Materials specified | Status | Date due | Barcode | |
|---|---|---|---|---|---|---|---|---|
Electronic-Books
|
OPJGU Sonepat- Campus | E-Books EBSCO | Available |
Includes bibliographical references and index.
Description based on print version record and CIP data provided by publisher.
English.
ANDROGENS ; ANDROGENS ; Contents ; Preface ; Androgen Deprivation Therapy for Advanced Prostate Cancer on the Ground of Androgen Milieu in the Prostate; Abstract ; Abbreviations ; Introduction; Androgen Milieu in Blood ; Androgen Milieu in the Prostate; Prostate Cancer Aggressiveness and the Androgen Milieu in the Prostate and in Blood ; Intraprostatic Androgen Milieu during Androgen Deprivation Therapy ; Androgen Milieu in the Castration-Resistant Prostate Cancer ; Clinical-Translational Advances of Prostate Cancer ; Gonadotrophin-Releasing Hormone (GnRH) Antagonists: Degarelix.
Cytochrome P450, Family 17, Subfamily A, Polypeptide 1 (CYP17A1) InhibitorsAbiraterone Acetate (Zytiga, Johnson & Johnson) ; Orteronel (TAK-700) [(1S)-1-(6,7-Dimethoxy-2-Naphthyl)-1-(1H-Imidazol-4-Yl)-2-Methylpropan-1-Ol] ; TOK-001 (VN/124-1) [3 -Hydroxy-17-(1H-Benzimidazole-1-Yl)Androsta-5,16-Diene] ; 3.-Hydroxysteroid Dehydrogenase Inhibitors; Apoptone (HE3235) (17 -Ethynyl-5 -Androstan-3, 17 -Diol) ; Inhibitors Targeting Androgen Receptor; A New Androgen Receptor Antagonist, MDV3100 ; A New Androgen Receptor Antagonist, ARN-509.
An Inhibitor of the Amino Terminal Domain (NTD) of the AR: EPI-001 The Prospects of the Androgen Deprivation Therapy on the Ground of Androgen Milieu in the Prostate ; Conclusion ; References ; Clinical Model of Androgen Deficiency -- Clinical Model of Androgen Deficiency -- Clinical Model of Androgen Deficiency -- Androgen Deprivation Therapy and Its Effect on Bone Metabolism, Metabolism and Cognitive Functions ; Introduction; Methods ; Androgen Deprivation Therapy (ADT) ; Testosterone: A Basal Overview of Biosynthesis, Metabolism and Its Action ; Androgens and Bone Metabolism.
ADT and Its Side Effects Bone Loss and Osteoporosis ; Osteoporosis; Diagnosis of Osteoporosis ; ADT, PCa and Clinical Aspects of Bone Disease ; Treatment of ADT Induced Osteoporosis ; Androgens and Cognitive Functions ; Potential Mechanisms of Action ; Cognitive Functions and ADT; Androgen Deprivation Therapy and Changes in Body Composition ; ADT and Insulin Resistance ; Early Metabolic Changes ; Late Metabolic Changes ; ADT and Lipid Alterations ; ADT, Metabolic Syndrome and Cardiovascular Disease ; References; The Role of Testosterone in Male Erectile Dysfunction.
1. Erectile Dysfunction 2. Definitions; 2.1. Total Testosterone ; 2.2. Free Testosterone ; 2.3. Bio-Available/Bioactive Testosterone ; 3. Hypogonadism ; 3.1. Late Onset Hypogonadism ; 3.2. Hypogonadism Prevalence ; 4. Relationship between Testosterone and ED ; 5. Physiology of Erection ; 6. Influence of Testosterone on Penile Erection ; 6.1. NOS/cGMP Pathway ; 6.2. Source of NO ; 6.3. Phosphodiesterases (PDE); 7. Making the Diagnosis of Hypogonadism and Working up Erectile Dysfunction ; Patient History ; Physical Exam ; Laboratory Studies ; Specific Diagnostic Tests ; 7.1. Questionnaires.
eBooks on EBSCOhost EBSCO eBook Subscription Academic Collection - Worldwide
There are no comments on this title.